Fig. 2: Acquired alterations in osimertinib-treated patients and in chemotherapy-treated patients. | Nature Communications

Fig. 2: Acquired alterations in osimertinib-treated patients and in chemotherapy-treated patients.

From: Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Fig. 2: Acquired alterations in osimertinib-treated patients and in chemotherapy-treated patients.

Tile plots indicating A acquired alterations in osimertinib-treated patients (n = 78) and B acquired alterations in chemotherapy-treated patients (n = 25) from the AURA3 trial. Source data are provided in the Supplementary Data 1 file. *C797S or C797G; †L792F or L792H. EGFR epidermal growth factor receptor.

Back to article page